PTPN11 and esophageal squamous cell carcinoma: Moreover, Kaplan-Meier analysis of The Cancer Genome Atlas (TCGA) survival data for ESCC patients demonstrated that patients with low expression of Shp2 exhibited worse overall survival (OS) compared with Shp2-high patients (median OS 763 versus 1361 days, p = 0.029; Figure 1D).